Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
All nitazoxanide studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchNitazoxanideNitazoxanide (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   
0 0.5 1 1.5 2+ Progression -188% Improvement Relative Risk Nitazoxanide  ANTICOV  EARLY TREATMENT  RCT Is early treatment with nitazoxanide + ciclesonide beneficial for COVID-19? RCT 905 patients in multiple countries Trial compares with paracetamol, results vs. placebo may differ Higher progression with nitazoxanide + ciclesonide (p=0.04) c19early.org ANTICOV, News, February 2022 Favors nitazoxanide Favors paracetamol

ANTICOV Trial Finds Nitazoxanide/Ciclesonide Drug Combination Does Not Reduce Hospitalisation Risk in Patients With Mild COVID-19

ANTICOV, News, ANTICOV, NCT04920838
Feb 2022  
  Post
  Facebook
Share
  Source   PDF   All   Meta
RCT with 462 nitazoxanide/ciclesonide and 443 paracetamol patients, up to 7 days from onset, showing no significant difference in progression. Minimal details, with the primary mortality outcome and treatment delay not being reported.
This study is excluded in the after exclusion results of meta analysis: minimal details provided.
risk of progression, 187.7% higher, RR 2.88, p = 0.04, treatment 15 of 462 (3.2%), control 5 of 443 (1.1%), SpO2 ≤ 93% within 14 days.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
ANTICOV et al., 28 Feb 2022, Randomized Controlled Trial, multiple countries, preprint, 1 author, this trial compares with another treatment - results may be better when compared to placebo, this trial uses multiple treatments in the treatment arm (combined with ciclesonide) - results of individual treatments may vary, trial NCT04920838 (history) (ANTICOV).
This PaperNitazoxanideAll
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit